Is Adicet Bio Stock a Good Investment?
Adicet Bio Investment Advice | ACET |
- Examine Adicet Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Adicet Bio's leadership team and their track record. Good management can help Adicet Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact Adicet Bio's business and its evolving consumer preferences.
- Compare Adicet Bio's performance and market position to its competitors. Analyze how Adicet Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Adicet Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Adicet Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Adicet Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Adicet Bio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Adicet Bio Stock
Researching Adicet Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 67.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.4. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adicet Bio has Price/Earnings To Growth (PEG) ratio of 0.82. The entity recorded a loss per share of 1.29. The firm last dividend was issued on the 16th of September 2020. Adicet Bio had 1:7 split on the 16th of September 2020.
To determine if Adicet Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adicet Bio's research are outlined below:
| Adicet Bio is way too risky over 90 days horizon | |
| Adicet Bio has some characteristics of a very speculative penny stock | |
| Adicet Bio appears to be risky and price may revert if volatility continues | |
| Adicet Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (117.12 M) with profit before overhead, payroll, taxes, and interest of 24.99 M. | |
| Adicet Bio currently holds about 260.64 M in cash with (92.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are held by institutions such as insurance companies |
Adicet Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adicet Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adicet Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Adicet Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.34 M.Basic technical analysis of Adicet Stock
As of the 19th of July, Adicet Bio shows the Mean Deviation of 4.69, risk adjusted performance of 0.1015, and Downside Deviation of 6.98. Adicet Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Adicet Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adicet Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adicet Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adicet Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adicet Bio's Outstanding Corporate Bonds
Adicet Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adicet Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adicet bonds can be classified according to their maturity, which is the date when Adicet Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Adicet Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Adicet Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1015 | |||
| Market Risk Adjusted Performance | 0.3301 | |||
| Mean Deviation | 4.69 | |||
| Semi Deviation | 5.54 | |||
| Downside Deviation | 6.98 | |||
| Coefficient Of Variation | 1006.16 | |||
| Standard Deviation | 7.0 | |||
| Variance | 48.97 | |||
| Information Ratio | 0.0793 | |||
| Jensen Alpha | 0.4055 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0795 | |||
| Treynor Ratio | 0.3201 | |||
| Maximum Drawdown | 36.06 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 10.77 | |||
| Downside Variance | 48.66 | |||
| Semi Variance | 30.68 | |||
| Expected Short fall | (5.55) | |||
| Skewness | 1.12 | |||
| Kurtosis | 4.18 |
| Risk Adjusted Performance | 0.1015 | |||
| Market Risk Adjusted Performance | 0.3301 | |||
| Mean Deviation | 4.69 | |||
| Semi Deviation | 5.54 | |||
| Downside Deviation | 6.98 | |||
| Coefficient Of Variation | 1006.16 | |||
| Standard Deviation | 7.0 | |||
| Variance | 48.97 | |||
| Information Ratio | 0.0793 | |||
| Jensen Alpha | 0.4055 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0795 | |||
| Treynor Ratio | 0.3201 | |||
| Maximum Drawdown | 36.06 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 10.77 | |||
| Downside Variance | 48.66 | |||
| Semi Variance | 30.68 | |||
| Expected Short fall | (5.55) | |||
| Skewness | 1.12 | |||
| Kurtosis | 4.18 |
Consider Adicet Bio's intraday indicators
Adicet Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adicet Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 16992.19 | |||
| Daily Balance Of Power | (0.60) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 0.78 | |||
| Day Typical Price | 0.77 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.03) | |||
| Relative Strength Index | 39.44 |
Adicet Stock media impact
There is far too much social signal, news, headlines, and media speculation about Adicet Bio that are available to investors today. This information is accessible both publicly - through Adicet Bio's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Adicet-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Adicet Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Adicet Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Adicet Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Adicet Bio alpha.
Adicet Bio Corporate Management
| Francesco MD | Chief VP | Profile | |
| BA CPA | Pres CEO | Profile | |
| Blake Aftab | Senior Officer | Profile | |
| Donald Healey | Chief Officer | Profile | |
| Amy Locke | Head Resources | Profile | |
| Brian Harvey | Chief Officer | Profile | |
| Julie MD | Chief Officer | Profile |
Already Invested in Adicet Bio?
The danger of trading Adicet Bio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adicet Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adicet Bio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adicet Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.